Biovica International AB (publ) has carried out a partially guaranteed new issue of units with preferential rights of approximately SEK 100 million before deduction of costs attributable to the rights issue.
Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica’s assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU.
Pareto Securities acted as Sole Bookrunner and Baker McKenzie acted as legal advisor to the company with a capital markets team consisting of Stefan Balazs, Joakim Falkner, Oscar Bang, Sophie Gidlund, Simon Olofsson and Carl Isaksson.